Lv61
1648 积分 2025-05-25 加入
Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults
1个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
1个月前
已完结
Comparison of Analysis of Covariance and Analysis of Variance in Pharmacokinetic Similarity Studies
3个月前
已完结
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial
4个月前
已完结
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
4个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
5个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial
5个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
5个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
5个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
5个月前
已完结
皖公网安备34019202002308
